Pure Global AI
NCT06384378Recruiting

Systemic and Central Inflammation in AD

Central and Peripheral Immune Cross-talk in Alzheimer's Disease and Their Modulation by a Novel Immunotherapy
The Methodist Hospital Research InstitutePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
11C-ER176
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Methodist Hospital Research Institute
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 17, 2023
End date
Dec 30, 2025
Enrollment
40 participants
Primary outcome

Blood inflammation biomarker levels,CSF inflammation biomarker levels,Voxel-wise, regional and total brain TSPO VT/fP measured with 11C-ER176 PET

Summary

Inflammation could provide a new focus for therapeutic intervention. In this study, we will
 measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to
 measurements of brain glial activation obtained by positron emission tomography (PET). In
 addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given
 over 22 weeks, on these inflammation biomarkers.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06384378
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06384378 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Methodist Hospital Research Institute and is currently Recruiting. The study focuses on Alzheimer Disease. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.